GlassScriptPhysician profile
Paul A Guillory
NPI 1114918281
$11,718.73
in general payments reported to CMS, 2019-2025
14 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,921 · 2020: $4,629 · 2021: $2,545 · 2022: $173 · 2023: $2,307 · 2024: $35.79 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $450.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $10,964.18 | 2019-2023 | |
| Optinose US, INC. | $257.46 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $140.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $110.11 | 2021-2025 | Nucala |
| Intersect Ent, INC. | $46.43 | 2019 | |
| Acclarent, INC | $45.45 | 2019 | |
| Genzyme Corporation | $34.72 | 2024-2025 | |
| Abbvie INC. | $30.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.46 | 2020 | |
| Olympus America INC. | $16.50 | 2019 | |
| Alk-Abello, INC | $14.99 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.53 | 2021 | |
| Axsome Therapeutics, INC. | $10.23 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Guillory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.